|
1
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bilello KS, Murin S and Matthay RA:
Epidemiology, etiology, and prevention of lung cancer. Clin Chest
Med. 23:1–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sundar R, Soong R, Cho BC, Brahmer JR and
Soo RA: Immunotherapy in the treatment of non-small cell lung
cancer. Lung Cancer. 85:101–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao J, Qiao CR, Ding Z, Sheng YL, Li XN,
Yang Y, Zhu DY, Zhang CY, Liu DL, Wu K and Zhao S: A novel pathway
in NSCLC cells: miR-191, targeting NFIA, is induced by chronic
hypoxia, and promotes cell proliferation and migration. Mol Med
Rep. 15:1319–1325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Centers for Disease Control and Prevention
(CDC), . Recent trends in mortality rates for four major cancers,
by sex and race/ethnicity-united states, 1990–1998. MMWR Morb
Mortal Wkly Rep. 51:49–53. 2002.PubMed/NCBI
|
|
6
|
Scott WJ, Howington J, Feigenberg S,
Movsas B and Pisters K; American College of Chest Physicians, :
Treatment of non-small cell lung cancer stage I and stage II: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132 Suppl 3:S234–S242. 2007. View Article : Google Scholar
|
|
7
|
Rosell R and Karachaliou N: Lung cancer:
Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin
Oncol. 10:549–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun SJ, Lin Q, Ma JX, Shi WW, Yang B and
Li F: Long non-coding RNA NEAT1 acts as oncogene in NSCLC by
regulating the Wnt signaling pathway. Eur Rev Med Pharmacol Sci.
21:504–510. 2017.PubMed/NCBI
|
|
9
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. Ca Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Li ZY, Hou XX, Wang X, Luo YH,
Ying YP and Chen G: Clinical significance and effect of AEG-1 on
the proliferation, invasion, and migration of NSCLC: A study based
on immunohistochemistry, TCGA, bioinformatics, in vitro and in vivo
verification. Oncotarget. 8:16531–16552. 2017.PubMed/NCBI
|
|
11
|
Vaya J, Belinky PA and Aviram M:
Antioxidant constituents from licorice roots: Isolation, structure
elucidation and antioxidative capacity toward LDL oxidation. Free
Radic Biol Med. 23:302–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan SC, Chang YS, Wang JP, Chen SC and
Kuo SC: Three new flavonoids and antiallergic, anti-inflammatory
constituents from the heartwood of dalbergia odorifera. Planta Med.
64:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamamoto S, Aizu E, Jiang H, Nakadate T,
Kiyoto I, Wang JC and Kato R: The potent anti-tumor-promoting agent
isoliquiritigenin. Carcinogenesis. 12:317–323. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma J, Fu NY, Pang DB, Wu WY and Xu AL:
Apoptosis induced by isoliquiritigenin in human gastric cancer
MGC-803 cells. Planta Med. 67:754–757. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanazawa M, Satomi Y, Mizutani Y, Ukimura
O, Kawauchi A, Sakai T, Baba M, Okuyama T, Nishino H and Miki T:
Isoliquiritigenin inhibits the growth of prostate cancer. Eur Urol.
43:580–586. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu YL, Kuo PL, Lin LT and Lin CC:
Isoliquiritigenin inhibits cell proliferation and induces apoptosis
in human hepatoma cells. Planta Med. 71:130–134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang KL, Hsia SM, Chan CJ, Chang FY, Huang
CY, Bau DT and Wang PS: Inhibitory effects of isoliquiritigenin on
the migration and invasion of human breast cancer cells. Expert
Opin Ther Targets. 17:337–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen XY, Li DF, Han JC, Wang B, Dong ZP,
Yu LN, Pan ZH, Qu CJ, Chen Y, Sun SG and Zheng QS: Reprogramming
induced by isoliquiritigenin diminishes melanoma cachexia through
mTORC2-AKT-GSK3β signaling. Oncotarget. 8:34565–34575.
2017.PubMed/NCBI
|
|
19
|
Hsu YL, Kuo PL, Chiang LC and Lin CC:
Isoliquiritigenin inhibits the proliferation and induces the
apoptosis of human non-small cell lung cancer a549 cells. Clin Exp
Pharmacol Physiol. 31:414–418. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao LJ, Li HD, Yan M, Li ZH, Gong H, Jiang
P, Deng Y, Fang PF and Zhang BK: The protective effects of
isoliquiritigenin and glycyrrhetinic acid against
triptolide-induced oxidative stress in hepG2 cells involve Nrf2
activation. Evid Based Complement Alternat Med. 2016:89121842016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie
T, Zhang J, Peng C, Lin Y and Chen J: MicroRNA-25 regulates
chemoresistance-associated autophagy in breast cancer cells, a
process modulated by the natural autophagy inducer
isoliquiritigenin. Oncotarget. 5:7013–7026. 2014.PubMed/NCBI
|
|
22
|
Wu CH, Chen HY, Wang CW, Shieh TM, Huang
TC, Lin LC, Wang KL and Hsia SM: Isoliquiritigenin induces
apoptosis and autophagy and inhibits endometrial cancer growth in
mice. Oncotarget. 7:73432–73447. 2016.PubMed/NCBI
|
|
23
|
Li Y, Zhao H, Wang Y, Zheng H, Yu W, Chai
H, Zhang J, Falck JR, Guo AM, Yue J, et al: Isoliquiritigenin
induces growth inhibition and apoptosis through downregulating
arachidonic acid metabolic network and the deactivation of PI3K/Akt
in human breast cancer. Toxicol Appl Pharmacol. 272:37–48. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu S, Xue J, Yang Y, Zhu H, Chen F, Wang
J, Lou G, Liu Y, Shi Y, Yu Y, et al: Isoliquiritigenin inhibits
interferon-γ-inducible genes expression in hepatocytes through
down-regulating activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK,
JNK/MAPK and PI3K/Akt signaling pathways. Cell Physiol Biochem.
37:501–514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu G, Zhang W, Bertram P, Zheng XF and
Mcleod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
|
26
|
Zhou Y and Ho WS: Combination of
liquiritin, isoliquiritin and isoliquirigenin induce apoptotic cell
death through upregulating p53 and p21 in the A549 non-small cell
lung cancer cells. Oncol Rep. 31:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao C, Wu CH and Hu HZ: LncRNA UCA1
promotes epithelial-mesenchymal transition (EMT) of breast cancer
cells via enhancing Wnt/beta-catenin signaling pathway. Eur Rev Med
Pharmacol Sci. 20:2819–2824. 2016.PubMed/NCBI
|
|
28
|
Magnaldo T and Sarasin A: Xeroderma
pigmentosum: From symptoms and genetics to gene-based skin therapy.
Cells Tissues Organs. 177:189–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Meier P, Finch A and Evan G: Apoptosis in
development. Nature. 407:796–801. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kerr JF, Wyllie AH and Currie AR:
Apoptosis: A basic biological phenomenon with wide-ranging
implications in tissue kinetics. Br J Cancer. 26:239–257. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Borner C: The Bcl-2 protein family:
Sensors and checkpoints for life-or-death decisions. Mol Immunol.
39:615–647. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown R: The bcl-2 family of proteins. Br
Med Bull. 53:466–477. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao H, Yenari MA, Cheng D, Sapolsky RM
and Steinberg GK: Bcl-2 overexpression protects against neuron loss
within the ischemic margin following experimental stroke and
inhibits cytochrome c translocation and caspase-3 activity. J
Neurochem. 85:1026–1036. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou GS, Song LJ and Yang B:
Isoliquiritigenin inhibits proliferation and induces apoptosis of
U87 human glioma cells in vitro. Mol Med Rep. 7:531–536. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jung JI, Chung E, Mi RS, Seon MR, Shin HK,
Kim EJ, Lim SS, Chung WY, Park KK and Park JH: Isoliquiritigenin
(ISL) inhibits ErbB3 signaling in prostate cancer cells.
Biofactors. 28:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang SW, Choi JS, Choi YJ, Bae JY, Li J,
Kim DS, Kim JL, Shin SY, Lee YJ, Kwun IS and Kang YH: Licorice
isoliquiritigenin dampens angiogenic activity via inhibition of
MAPK-responsive signaling pathways leading to induction of matrix
metalloproteinases. J Nutr Biochem. 21:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim N, Jeong S, Jing K, Shin S, Kim S, Heo
JY, Kweon GR, Park SK, Wu T, Park JI and Lim K: Docosahexaenoic
acid induces cell death in human non-small cell lung cancer cells
by repressing mTOR via AMPK activation and PI3K/akt inhibition.
Biomed Res Int. 2015:2397642015.PubMed/NCBI
|
|
39
|
Li YC, He SM, He ZX, Li M, Yang Y, Pang
JX, Zhang X, Chow K, Zhou Q, Duan W, et al: Plumbagin induces
apoptotic and autophagic cell death through inhibition of the
PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.
Cancer Lett. 344:239–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
